1786 Stock Overview
Engages in the production and sale of hyaluronic acid medical products in Taiwan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
SciVision Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$136.50 |
| 52 Week High | NT$144.00 |
| 52 Week Low | NT$72.20 |
| Beta | 0.67 |
| 11 Month Change | 23.53% |
| 3 Month Change | 30.00% |
| 1 Year Change | 56.00% |
| 33 Year Change | 171.25% |
| 5 Year Change | 117.19% |
| Change since IPO | 352.25% |
Recent News & Updates
SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings
Aug 30
SciVision Biotech's (TWSE:1786) Upcoming Dividend Will Be Larger Than Last Year's
Jul 22Recent updates
SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings
Aug 30SciVision Biotech's (TWSE:1786) Upcoming Dividend Will Be Larger Than Last Year's
Jul 22SciVision Biotech (TWSE:1786) Has Announced That It Will Be Increasing Its Dividend To NT$2.50
Jun 28SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings
Jun 14SciVision Biotech (TWSE:1786) Seems To Use Debt Rather Sparingly
Jun 04Some Shareholders Feeling Restless Over SciVision Biotech Inc.'s (TWSE:1786) P/E Ratio
Apr 01Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly
Apr 20SciVision Biotech (TPE:1786) Is Looking To Continue Growing Its Returns On Capital
Apr 02Can You Imagine How SciVision Biotech's (TPE:1786) Shareholders Feel About The 33% Share Price Increase?
Mar 15Read This Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend
Feb 25Could The Market Be Wrong About SciVision Biotech Inc. (TPE:1786) Given Its Attractive Financial Prospects?
Feb 05Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly
Jan 18Will The ROCE Trend At SciVision Biotech (TPE:1786) Continue?
Jan 01
SciVision Biotech (TPE:1786) Shareholders Booked A 80% Gain In The Last Three Years
Dec 14Key Things To Consider Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend
Nov 25Shareholder Returns
| 1786 | TW Medical Equipment | TW Market | |
|---|---|---|---|
| 7D | 4.2% | 0.4% | 0.6% |
| 1Y | 56.0% | 19.4% | 32.9% |
Return vs Industry: 1786 exceeded the TW Medical Equipment industry which returned 19.4% over the past year.
Return vs Market: 1786 exceeded the TW Market which returned 32.9% over the past year.
Price Volatility
| 1786 volatility | |
|---|---|
| 1786 Average Weekly Movement | 7.6% |
| Medical Equipment Industry Average Movement | 4.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in TW Market | 9.3% |
| 10% least volatile stocks in TW Market | 3.0% |
Stable Share Price: 1786's share price has been volatile over the past 3 months.
Volatility Over Time: 1786's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | n/a | Tai Xian Han | www.scivision.com.tw |
SciVision Biotech Inc. engages in the production and sale of hyaluronic acid medical products in Taiwan and internationally. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. It is also involved in the wholesale of medical equipment; and provides management consulting services.
SciVision Biotech Inc. Fundamentals Summary
| 1786 fundamental statistics | |
|---|---|
| Market cap | NT$9.32b |
| Earnings (TTM) | NT$213.44m |
| Revenue (TTM) | NT$815.25m |
43.7x
P/E Ratio11.4x
P/S RatioIs 1786 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1786 income statement (TTM) | |
|---|---|
| Revenue | NT$815.25m |
| Cost of Revenue | NT$206.31m |
| Gross Profit | NT$608.94m |
| Other Expenses | NT$395.50m |
| Earnings | NT$213.44m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.13 |
| Gross Margin | 74.69% |
| Net Profit Margin | 26.18% |
| Debt/Equity Ratio | 12.1% |
How did 1786 perform over the long term?
See historical performance and comparison